Maternal and perinatal outcome of patients with severe pre-eclampsia in a tertiary health centre in south-western Nigeria: a cohort study by Lamina, M.A. et al.
Maternal and perinatal outcome of patients with severe pre-eclampsia 
in a tertiary health centre in south-western Nigeria: a cohort study
*Lamina M A, Akinsanya A F and Ogunsowo KM
Original Article
ABSTRACT
Objective: To determine the effect of introducing MgSO  on the maternal and perinatal outcomes of 4
severe pre-eclampsia in Sagamu, south-western Nigeria.
Methods: A retrospective cohort study of all cases of severe pre-eclampsia managed at Olabisi Onabanjo 
University Teaching Hospital (OOUTH), Sagamu, Nigeria from 1 January 2001 to 31 December 2012 – 6 
years before and 6 years after the introduction of MgSO  was carried out.4
Results: The prevalence of severe pre-eclampsia within the study period was 4.2%. The mean age of study 
participants was 31.2 ± 6.7 years. Seventy-four women received MgSO while 123 received diazepam. 4 
Eclampsia occurred in 3 members of the diazepam group and none in the MgSO group. There were no 4 
maternal deaths. Babies from the diazepam group were more likely to have low Apgar score at 5 minutes 
(though the association was not statistically significant [OR=1.47, 95% CI 0.76, 2.82]).Babies from the 
diazepam group were significantly more likely to have prolonged hospital stay [OR= 6.09, CI 2.25, 17.40; 
p< 0.001] and suffer early neonatal deaths than babies from the MgSO  group [OR= 5.26, CI 1.35, 23.92; 4
p= 0.005]. Perinatal mortality did not differ between the groups.
Conclusion: MgSO is more effective than diazepam in the management of severe pre-eclampsia at 4 
OOUTH, Sagamu, Nigeria. Therefore, its accessibility and wider use should be promoted to improve 
fetomaternal outcome.
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RÉSUMÉ
Objectif : Cette étude vise à déterminer l'impact de l'introduction de  sur les résultats maternels et  
périnataux de pré-éclampsie graves à Sagamu, au sud-ouest du Nigeria.
Méthode : Nous avons effectué une étude rétrospective de tous les cas de pré-éclampsie graves soignées 
au Centre Hospitalier Universitaire de l'Université Olabisi Onabanjo (OOUTH), Sagamu au Nigeria du 
1er janvier 2001 au 31 décembre 2012 – 6 ans avant et 6 après l'introduction du MgSO4.
Résultats majeurs : la prévalence de pré-éclampsie grave au cours de la période d'étude était de 4,2%. La 
moyenne d'âge des participants à cette étude était de 31,2±6,7 ans. Soixante-quatorze femmes ont reçu du 
MgSO tandis que 123 ont reçu du diazépam. L'éclampsie s'est signalée chez 3 membres du groupe de 
4diazépam et chez personne dans le groupe de MgSO  . Il n'y a eu aucune mort maternelle. Les enfants 4
issus 4du groupe de diazépam présentaient plus de chance d'avoir un indice d'Apgar bas à 5 minutes 
(quoique lerapport n'était pas statistiquement important [OR=1,47 ; 95% CI 0,76 ; 2,82]). Les enfants issus 
du groupe de diazépam présentaient plus de chances d'avoir un séjour hospitalier prolongé [OR=6,09 ; CI 
2,25 ;17,40 ; p? 0,001] et souffrent de morts néonatales précoces plus que les enfants issus du groupe de 
MgSO  [OR=5,26 ; CI 1,35 ; 23,92 ; p=0,005]. La mortalité périnatale était la même dans les groupes.4
Conclusion : le MgSO  est plus efficace que le Diazépam dans les soins administrés pour le traitement de 4
4pré-éclampsie grave à OOUTH, Sagamu au Nigeria. Par conséquent, nous devons encourager 
sonaccessibilité et son grand usage dans le but d'améliorer les résultats foeto-maternels.
Mots-clés : Pré-éclampsie grave, crise prophylaxie, mortalité périnatale, sulfate de magnésium, Nigeria.
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INTRODUCTION
Hypertension is one of the most 
common medical complications of 
pregnancy and affects both maternal and fetal 
health. Hypertensive disorders during 
pregnancy remain one of the leading causes 
of maternal death worldwide, accounting for 
10 to 20 per cent of maternal deaths (1). 
Hypertensive disease complicates 5-
7 percent of all pregnancies. It can be 
categorized into pre-existing hypertension, 
pregnancy-induced hypertension and pre-
eclampsia. Pre-eclampsia is a syndrome 
occurring only in pregnancy and puerperium 
and defined by new onset of hypertension 
after  the 20 weeks of  pregnancy 
accompanied by a new onset (significant) 
proteinuria (2).Pre-eclampsia complicates 
about 5 – 10% of pregnancies (2). Together 
with its major complications- eclampsia and 
HELLP syndrome, it is an important cause of 
maternal and perinatal morbidity and 
mortality both in Nigeria and globally 
(3,4).Its effective management and/or 
prevention of eclampsia would therefore 
contribute significantly to reduction in 
maternal and perinatal morbidity and 
mortality (5).
Though the exact etiology of pre-
eclampsia is not known, some of the potential 
etiologies include abnormal placentation, 
immunological intolerance between feto-
placental and maternal tissues, dietary 
deficiencies and genetic predisposition. 
Although the exact etiology remains elusive, 
two basic abnormalities are consistently seen 
in pre-eclampsia- abnormal trophoblastic 
invasion of uterine blood vessels and 
endothelial cell dysfunction (6),which may 
explain why significant improvement in the 
maternal clinical condition is not achieved 
until the placenta is delivered.
Pre-eclampsia is a multisystem 
disorder. It can be divided further into mild 
and severe types. Severe pre-eclampsia is 
characterized by severe hypertension and 
s ignif icant  prote inur ia  (1 ,2) .  The 
management of severe pre-eclampsia entails 
the use of antihypertensive drugs to control 
the blood pressure, anticonvulsants for 
seizure prophylaxis and delivering the fetus 
as soon as it is viable. Seizure prophylaxis 
employs the use of drugs such as diazepam, 
phenytoin and magnesium sulfate (MgSO ) 4
(6). There is overwhelming evidence to 
suggest that MgSO is superior to other 4
anticonvulsants in the management of severe 
pre-eclampsia/eclampsia (8). In line with 
this, there has been increasing use of MgSO  4
in health institutions in Nigeria (9,10). From 
the year 2007, the use of intramuscular 
MgSO  regimen replaced diazepam in the 4
protocol for the management of pre-
eclampsia/eclampsia at the Olabisi Onabanjo 
University Teaching Hospital (OOUTH), 
Sagamu, Nigeria.
MATERIALS AND METHODS
This was a retrospective study of 2 
cohorts of women managed for severe pre-
eclampsia at the Olabisi Onabanjo University 
Teaching Hospital (OOUTH), Sagamu, 
Nigeria from 2001 to 2012. The first 
(Diazepam) cohort consisted of those 
managed from January 2001 to December 
2006 and received Roche brand of Diazepam 
as infusion of 20mg in 500mls of intravenous 
fluid over 6 hours, and continued for 24 hours 
after delivery as seizure prophylaxis. The 
second (MgSO ) cohort was made of those 4
managed from January 2007 (to December 
2012) when MgSO  was introduced as 4
seizure prophylaxis. The modified form of 
Sibai regimen (11,12) consisting of a starting 
dose of 4 grams of MgSO  given 4
intravenously, followed by 2 grams of 
MgSO  intravenously every 4 hours was 4
adopted by the Department of Obstetrics and 
Gynaecology of the hospital. Those women 
with history of seizure prior to admission and 
chronic hypertension were excluded from the 
study.
The case notes of the patients were 
retrieved from the Medical Information 
Department of the hospital. Patients' biodata 
and relevant outcome variables were sought 
for and recorded in a data sheet prepared for 
the study. Maternal outcome variables were 
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the occurrence of seizure (eclampsia) after 
initiation of seizure prophylaxis, duration of 
hospital stay, and maternal deaths. Perinatal 
outcome variables were Apgar score at 1 and 
5 minutes, perinatal deaths, and early 
neonatal deaths. The ethical approval to 
conduct this study was given by Research 
Ethics Review Committee of the Hospital. 
Data were analyzed by both 
descriptive and inferential statistics at 95% 
confidence level using SPSS software for 
Windows version 17.0. Frequency tables 
were generated for relevant variables. 
Proportions were compared using the 
Pearson chi-square test. Relationships were 
expressed using odds ratio and confidence 
intervals.
The diagnosis of severe pre-
eclampsia was made in a woman with pre-
eclampsia in line with standard protocols 
which include a diastolic blood pressure 
equal to or greater than (≥) 110 mmHg and or 
systolic blood pressure ≥ 160 mmHg or urine 
protein is ≥ 5g/24 hours (8).A low Apgar 
score at 1 and/or 5 minutes was defined as a 
score less than 7.Prolonged hospital stay was 
defined as a hospital stay of more than 7 days 
following caesarean section or more than 2 
days following vaginal delivery.
The Olabisi Onabanjo University 
Teaching Hospital (OOUTH), Sagamu, 
Nigeria is a teaching hospital which offers 
both primary and specialist care to pregnant 
women in Ogun State of Nigeria and its 
environment. It provides emergency 
obstetric services to women referred from 
other centers in addition to providing 
antenatal care and delivery services for low 
and high risk pregnant women from Sagamu 
community and neighboring towns. 
However, the proportion of booked pregnant 
patients that eventually deliver at OOUTH is 
less than 50%. In a study carried out in this 
hospital by Lamina et. al (13), it was found 
out that 28% of pregnant patients who 
booked at the center eventually delivered 
there. Attitude of hospital staff, cost of 
services and distance of the hospital from 
patient's homes were some of the reasons 
given for not wanting to deliver at the 
Teaching Hospital and hence, the low 
delivery rate.
RESULT
During the 12year study period, there 
were 197 cases of severe pre-eclampsia and 
4682 deliveries which gave a prevalence rate 
of 4.2%. The mean age of the participants 
were 31.2 ± 6.7 years with a range of 19 – 48 
years. The modal age group was 30 – 39 years 
and it consisted of 91 (46.2%) women. Sixty-
five (33%) women registered and received 
antenatal care at the study center while the 
remaining (132; 67%) women were referred. 
A sizeable proportion of participants (81; 
41.1%) were primigravidae, and the 
commonest gestational age at presentation 
was 34 – 36 weeks. Details of the socio-
demographic data and other characteristics 
are shown in Table 1.
The diazepam cohort consisted of 
123 women while the MgSO  cohort had 74 4
women. None of the patients in the MgSO  4
group had seizures after the commencement 
of the drug. Three women in the diazepam 
group had 2 to 4 episodes of tonic clonic 
seizures each. There were no maternal deaths 
in either of the groups.
Fifty-seven neonates from the 
diazepam group had low Apgar score at 1 
minute as against 35 neonates from the 
MgSO  group. There was no statistical 4
significant difference in terms of propensity 
of babies from either group to low Apgar 
score at 1 minute [OR= 0.84,CI 0.45 1.56]. 
On the other hand, 32 and 14 neonates from 
the  d iazepam and MgSO  groups  4
respectively had low Apgar score at 5 
minutes. Babies from diazepam group were 
more likely to have low Apgar score at 5 
minutes but the association was not 
statistically significant [OR= 1.47, CI 0.76, 
2.82]. Table 2 shows the details of the 
relationships between the MgSO  and 4
diazepam groups with respect to Apgar 
scores.
Furthermore, out of the 197 women 
studied, 169 (85.8%) had a prolonged 
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hospital stay: 53 (71.6%) women in the 
MgSO  group and 116 (94.3%) in the 4
diazepam group. The observed difference 
was statistically significant [OR= 6.09, CI 
2.25, 17.40, p< 0.001]
One hundred and ninety-seven pre-
eclamptic women delivered 201 babies (4 
were twin deliveries): 73 babies died within 
the perinatal period giving a perinatal case 
fatality rate of 36.3%. There were 23 
perinatal deaths (21 stillbirths and 2 early 
neonatal deaths) in the MgSO  group which 4
did not vary significantly with the 50 
perinatal deaths (32 stillbirths and 18 early 
neonatal deaths) in the diazepam group 
(Tables 3 and 4). However, there was 
statistical significant difference between the 
two groups in terms of early neonatal deaths, 
babies in the diazepam group had more 
propensity to suffer early neonatal death than 
babies in the MgSO group [OR= 5.26, 4 
CI1.35, 23.92, p< 0.05]. Forty-nine stillbirths 
occurred in 132 mothers who were referred 
while 4 stillbirths occurred in 65 mothers 
who were booked. Babies who were born by 
mothers who were referred were more likely 
to suffer stillbirth than babies who were born 
by mothers who were booked (OR=9.20, CI 
3.45, 25.89, p < 0.05). The perinatal mortality 
rates were 48.5% and 13.9% for babies born 
by referred and booked mothers respectively 
(OR=5.67, CI2.72, 11.99, p< 0.05). 
DISCUSSION
Pre-eclampsia is a common and 
potential serious complication of pregnancy. 
The severe type occurs in about 25% of all 
cases of pre-eclampsia (8). The prevalence of 
severe pre-eclampsia of 4.2% observed in 
this study is similar to 5% in United Kingdom 
population (14) but higher than 0.3% 
reported from Nepal, South Asia (15). About 
two-thirds (67%) of all cases identified in this 
study were referred and they contributed 
significantly to the perinatal mortality. This 
underscores the importance of antenatal care 
and early recognition and prompt referral to 
hospitals where specialist care can be 
provided so as to prevent its complications 
and improve feto-maternal outcome. The 
participants' mean age, parity and gestational 
age distribution of the cases were similar to 
those from related report (16-18).
The superior efficacy of MgSO  in the 4
management of pre-eclampsia/eclampsia has 
been confirmed (19).This modified regimen 
is prescribed at the study center in preference 
to Pritchard(18) and other regimens because 
of low cost, ease of administration and 
unavailability (lack) of infusion pumps (20). 
The use of MgSO  as seizure prophylaxis in 4
cases of severe pre-eclampsia reduces the 
risk of progression to eclampsia by more than 
half (8). This was evident in this study where 
eclampsia was observed only in the diazepam 
group. Furthermore, it may not be surprising 
that no maternal death was recorded in this 
study irrespective of the type of seizure 
prophylaxis because prompt commencement 
of seizure prophylaxis and prompt delivery in 
severe pre-eclampsia is associated with 
lower incidence of maternal death (8).
In this study, a newborn with a low 5-
minute Apgar score was 1.47 times more 
likely to belong to a woman who received 
diazepam as seizure prophylaxis, when 
compared to the MgSO group, though the 4 
association was not statistically significant. 
Low Apgar score has been associated with 
use of diazepam as seizure prophylaxis in 
pre-eclampsia. It has been suggested that 
diazepam crosses the placenta at a substantial 
dose to affect the fetus, causing depression of 
respiration in the newborn from cumulative 
effect of diazepam (8).Therefore, it is 
pertinent to ensure the availability of basic 
skills and equipment for newborn 
resuscitation not only in centers where 
diazepam is still being used for management 
of severe pre-eclampsia but also in centers 
where the use of MgSO has been instituted 4 
because a substantial number of babies from 
the women in the latter group also suffered 
low Apgar score (birth asphyxia). The reason 
for the observed significant increase in 
hospital stay among the diazepam group was 
not clear and calls for further studies.
Severe pre-eclampsia is also 
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injurious to the fetus and this was reflected in 
the study by the high proportion (56.9%) of 
low birth weight babies and high perinatal 
case fatality of 36.3%. Nevertheless, the 
likelihood of perinatal death did not vary 
significantly between the MgSO and 4 
diazepam groups.
Limitations: The study is limited by its 
retrospective nature and dependence on 
patient's records. It is likely that substantial 
measurement bias might have occurred 
especially with Apgar scoring but it was 
probably non-directional and therefore, 
would not have affected the study in any 
direction. It was also assumed that patients' 
management in either group was strictly in 
line with the hospital's protocol but that 
might not have been the case in our 
environment where payment for health care 
is essentially out of pocket. Furthermore, a 
larger number of participants could have 
produced more precise significant study 
results. Despite these limitations, the study 
has initiated the process of filling the existing 
gap on severe pre-eclampsia and the use of 
MgSO in our environment.4 
CONCLUSION 
This study has shown reduced 
perinatal morbidity (low Apgar score) and 
maternal morbidity (eclampsia and longer 
hospital stay) among severe pre-eclamptic 
women who received MgSO when compared 4
to those who receive diazepam. These 
findings support the superiority of MgSO in 4 
the management of severe pre-eclampsia. It 
is pertinent to improve the accessibility and 
wider use of MgSO as part of our nation's 4
struggle to achieve the much desired 
reduction in maternal and perinatal mortality.
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Table 1: Characteristics of study participants  
Age (years) Number Percentage 
< 20 7 3.6 
20 – 29 82 41.6














No formal education 
Primary
21 







Gestational age range (weeks)
Less than 29 11 5.6
29 – 33 41 20.8
34 – 36 43 21.8
37 42 99 0.3
Greater than 42 3 1.5
Total 197 100.0
 
Route of delivery  
Spontaneous vertex delivery  85 43.2
Assisted breech delivery 2 1.0
Vacuum delivery 5 2.5
Caesarean section 105 53.3
Total 197 100.0
Birth weight
Less than 1.5kg 35 17.4
1.5 – 2.49kg 79 39.3
2.5 4.0 85 42.3
Greater than 4.0kg 2 1.0
Total 201 100.0
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Low Apgar score at 1 minute
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Low Apgar score at 5 minute
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0.0052861 5.26  1.35, 
23.92  
MgSO4  21              
(28.0)
  2                       
(2.7)
23   
Total  53                        20                       73   
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